Benralizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Benralizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD125
Clinical data
Pronunciationben" ra liz' ue mab
Trade namesFasenra
AHFS/Drugs.comMonograph
MedlinePlusa618002
License data
Pregnancy
category
  • AU: B1
Routes of
administration
Subcutaneous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only [1]
Identifiers
CAS Number
  • 1044511-01-4 ☒N
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6492H10060N1724O2028S42
Molar mass146056.45 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody medication which is developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).[2][3]

Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016.[4][5] It was approved by the US Food and Drug Administration in November 2017 for the treatment of severe eosinophilic asthma.[6] It was granted designation as an orphan drug by the Food and Drug Administration for treatment of eosinophilic oesophagitis in August 2019.[7]

References[edit]

  1. ^ "Fasenra EPAR". European Medicines Agency (EMA). Retrieved 13 October 2020.
  2. ^ Statement on a Nonproprietary Name adopted by the USAN Council: Benralizumab
  3. ^ Catley MC (September 2010). "Asthma & COPD--IQPC's Second Conference". IDrugs. 13 (9): 601–4. PMID 20799138.
  4. ^ AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies. Sept 2016
  5. ^ Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. (June 2017). "Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma". The New England Journal of Medicine. 376 (25): 2448–2458. doi:10.1056/NEJMoa1703501. PMID 28530840.
  6. ^ "Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma". AstraZeneca. 2017-11-14.
  7. ^ "Fasenra granted US Orphan Drug Designation for eosinophilic oesophagitis". www.astrazeneca.com. Retrieved 2019-10-29.

External links[edit]

  • "Benralizumab". Drug Information Portal. U.S. National Library of Medicine.